GlassScriptPhysician profile
Mary E Ferebee
NPI 1659601094
$3,230.14
in general payments reported to CMS, 2019-2025
21 companies · $824 in 2025
The $824 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $301 · 2023: $821 · 2024: $1,141 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.92 |
| Education | $103.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,198.13 | 2021-2025 | |
| Janssen Biotech, INC. | $507.03 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.48 | 2021-2024 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $217.78 | 2021-2025 | |
| Genzyme Corporation | $195.71 | 2022-2025 | |
| Evoke Pharma, INC. | $112.35 | 2024-2025 | |
| Qol Medical, LLC | $104.15 | 2021-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $73.10 | 2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $72.32 | 2021-2024 | Entyvio |
| Ardelyx, INC. | $70.28 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $62.49 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $59.00 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $56.43 | 2021-2023 | Talicia |
| Pfizer INC. | $55.35 | 2025 | |
| Olympus America INC. | $26.90 | 2023 | Visera 4k Uhd Camera Control Unit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.38 | 2021 | |
| Mauna Kea Technologies, INC. | $21.69 | 2025 | |
| Novo Nordisk INC | $20.72 | 2025 | Wegovy |
| Exact Sciences Corporation | $20.51 | 2025 | Cologuard Collection Kit |
| Celgene Corporation | $16.51 | 2023 | Zeposia |
| Celltrion USA INC. | $13.83 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ferebee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.